ALARIS Medical Systems' Underwriters Exercise Over-Allotment Option.Business Editors/Health/Medical Writers SAN DIEGO--(BUSINESS WIRE)--July 2, 2003 ALARIS Medical Systems Inc. (AMEX AMEX See: American Stock Exchange :AMI) announced today that the underwriters of the company's recent public offering of common stock have exercised their over-allotment option in full to purchase an additional 1,350,000 shares of common stock. As previously disclosed, the over-allotment includes an additional 900,000 shares from the company and 450,000 shares from selling stockholders. This purchase combined with the 9,100,000 shares originally offered by the company brings to 10,450,000 the total number of shares offered. The public offering price was $12.50 per share. The company received net proceeds Net Proceeds The amount received after all costs are deducted from the sale of a piece of property or security. Notes: In the case of an investor selling a security, net proceeds represent the proceeds from the sale minus any trading costs (i.e. commissions). of approximately $118.4 million from the sale of the 10,000,000 shares it offered. The company received none of the proceeds from the shares sold by the selling stockholders other than proceeds received upon the exercise of stock options underlying the shares they have sold. The joint book-running managers of the equity offering were Bear, Stearns & Co. Inc., CIBC World Markets CIBC World Markets is the investment banking division of the Canadian Imperial Bank of Commerce. It helps governments, large companies, and other large institutions obtain capital and credit and is a primary dealer in U.S. Treasury securities. Corp. and UBS UBS Union Bank of Switzerland UBS United Bible Societies UBS United Blood Services UBS United Buying Service UBS Used Bookstore UBS University Business Services UBS Universal Building Society (UK) UBS Ulaanbaatar Broadcasting System Securities LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control . This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities. Offers, solicitations and sales may be made only by means of the prospectus copies of which may be obtained from these underwriters or from the company. About ALARIS Medical Systems Inc. ALARIS Medical Systems Inc. develops practical solutions for medication safety. The company designs, manufactures and markets intravenous (IV) medication delivery and infusion therapy devices, needle-free disposables and related monitoring equipment in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. and internationally. ALARIS Medical Systems' proprietary Guardrails(R) Safety Software, its other "smart" technologies and its "smart" services help to reduce the risks and costs of medication errors, help to safeguard patients and clinicians and also gather and record clinical information for review, analysis and transcription. The company provides its products, professional and technical support and training services to over 5,000 hospital and health care systems, as well as alternative care sites, in more than 120 countries through its direct sales force and distributors. With headquarters in San Diego San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. , ALARIS Medical Systems employs approximately 2,900 people worldwide. Additional information on the company can be found at http://www.alarismed.com. This news release contains forward-looking statements as defined in the Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Persons reading this release are cautioned that such forward-looking statements involve risks and uncertainties, including the significant leverage to which the company is subject. Such risk factors are detailed in the Securities and Exchange Commission filings of ALARIS Medical Inc. and ALARIS Medical Systems Inc., including Forms 10-K for the year ended Dec. 31, 2002, and other filings. The company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion